Abstract
Campylobacter jejuni is most prevalent pathogen borne diseases in recent decades. The Commonness and frequency of occurrence are rising in both emerging and developed countries. Campylobacter is a prominent etiological agent of foodborne illness, responsible for about one million cases each year. Infections caused by this bacterium can result in diarrhea and a range of other gastrointestinal issues. This study is focused on exploring the potential drug target in pathogenic C. jejuni and discovering novel medications to suppress the activity of the pathogen. The detection of drug targets commences with the detection of targets that lack homology to human or gut microbiota proteins. This process entails the identification of key proteins, locating those that exhibit strong interactions with these essential proteins and are vital for sustaining the stability of the protein network. Cytoplasmic proteins with distinct pathways and recognized molecular functions are subsequently identified, followed by an evaluation of non-druggable proteins. By this method one protein drug target has been identified with lipid A disaccharide synthase metabolism. It has been performed through Schrodinger and molecular dynamic study in DESMOND. The identified drug target showed high binding affinity with Tinocordiside, a herbal compound which is isolated from Giloy and Yuccagenin, the fenugreek seeds. This study concludes that the herbal compounds Yuccagenin and the identified potential drug target can be taken for the drug therapeutic process and developing novel pharmaceutical formulations to modulate the biological activity of C. jejuni, a pathogen responsible for foodborne infections. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40203-026-00563-1.